U.S. Food and Drug Administration, Center for Drug Evaluationand Research (CDER). Guidance for Industry: Bioavailability and BioequivalenceStudies for Orally Administered Drug Products—General Considerations,March (2003; Division of Drug Information Branch, HFD-240,Center for Drug Evaluation and Research, FDA:Rockville, MD;http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf.
European Medicines Agency (EMEA) Committeefor MedicinalProducts for Human Use. Guideline on the Investigation of Bioequivalence;Doc.Ref.: CPMP/EWP/QWP/1401/98Rev.1/Corr; EMEA:London, January 20, 2010; http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
Amidon G. L., 1995, Pharm. Res., 12, 413, 10.1023/A:1016212804288
Polli J. E., 2008, AAPS J., 10, 373, 10.1208/s12248-008-9040-9
Chen M.-L., 2011, Pharm. Res., 28, 1774, 10.1007/s11095-011-0438-1
U.S. Food and Drug Administration, Center for Drug Evaluationand Research (CDER). Guidance for Industry: Waiver of In Vivo Bioavailabilityand Bioequivalence Studies for Immediate-Release Solid Oral DosageForms Based on a Biopharmaceutics Classification System, August (2000; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf.
Cook J., 2008, AAPS J., 10, 306, 10.1208/s12248-008-9036-5
Ku M. S., 2008, AAPS J., 10, 208, 10.1208/s12248-008-9020-0
Lennernäs H., 2005, J. Pharm. Pharmacol., 57, 273, 10.1211/0022357055263
Cao X., 2006, Pharm. Res., 23, 1675, 10.1007/s11095-006-9041-2
Dahan A., 2010, Mol. Pharmaceutics, 7, 1827, 10.1021/mp100175a
Dahan A., 2009, Pharm. Res., 26, 883, 10.1007/s11095-008-9789-7
Volpe D. A., 2011, Future Med. Chem., 3, 2063, 10.4155/fmc.11.149
Hubatsch I., 2007, Nat. Protocols, 2, 2111, 10.1038/nprot.2007.303
Kim J.-S., 2006, Mol. Pharmaceutics, 3, 686, 10.1021/mp060042f
Dahan A., 2008, Mol. Pharmaceutics, 6, 19, 10.1021/mp800088f
Regårdh C. G., 1974, J. Pharmacokinet. Biopharm., 2, 347, 10.1007/BF01061407
Volpe D. A., 2004, AAPS Pharm. Sci., 6, 1, 10.1208/ps060213
Volpe D. A., 2007, Clin. Res. Reg. Affairs, 24, 39, 10.1080/10601330701273669
Thiel-Demby V. E., 2008, Mol. Pharmaceutics, 6, 11, 10.1021/mp800122b
Jappar D., 2010, Drug. Metab. Dispos., 38, 1740, 10.1124/dmd.110.034025
Fagerholm U., 1996, Pharm. Res., 13, 1336, 10.1023/A:1016065715308
Meier J., 1982, Am. Heart J., 104, 364, 10.1016/0002-8703(82)90127-2
Jobin G., 1985, Br. J. Clin. Pharmacol., 19, 97S, 10.1111/j.1365-2125.1985.tb02749.x
Vidon N., 1985, Br. J. Clin. Pharmacol., 19, 107S, 10.1111/j.1365-2125.1985.tb02750.x
Martin L. E., 1976, Br. J. Clin. Pharmacol., 3, 695
McNeil J. J., 1979, Br. J. Clin. Pharmacol., 8, 157S, 10.1111/j.1365-2125.1979.tb04773.x
Fujimura A., 1989, J. Clin. Pharmacol., 29, 635, 10.1002/j.1552-4604.1989.tb03392.x
Hoffman B. B., 2001, The Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10, 215
Dollery C., 1991, Therapeutic Drugs, 2, L1
Wagner J. G., 1991, J. Pharmacokinet. Biopharm., 19, 413, 10.1007/BF01061665
Wu C.-Y., 2005, Pharm. Res., 22, 11, 10.1007/s11095-004-9004-4
Product Information Trandate (labetalol hydrochloride) Tablets, FDA;http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018716s026lbl.pdf.
Draft Guidance on Labetalol Hydrochloride, FDA;http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194633.pdf.
Yang Y., 2007, Mol. Pharmaceutics, 4, 608, 10.1021/mp070028i
Moss A. M., 2012, Mol. Pharmaceutics, 9, 2442, 10.1021/mp200647a
Holmstock N., 2012, Drug Metab. Dispos., 40, 1473, 10.1124/dmd.112.044677
Holmstock N., 2010, Drug Metab. Dispos., 38, 1407, 10.1124/dmd.110.032771
Escribano E., 2012, Int. J. Pharm., 436, 472, 10.1016/j.ijpharm.2012.07.010
Shalaeva M., 2008, J. Pharm. Sci., 97, 2581, 10.1002/jps.21287
Martínez V., 2000, J. Pharm. Biomed. Anal., 23, 459, 10.1016/S0731-7085(00)00324-1
Henchoz Y., 2009, Anal. Bioanal. Chem., 394, 1919, 10.1007/s00216-009-2862-1
Burgot G., 1990, Int. J. Pharm., 63, 73, 10.1016/0378-5173(90)90103-B
Abushammala I., 2006, J. Pharm. Sci., 95, 1733, 10.1002/jps.20639
Neuhoff S., 2003, Pharm. Res., 20, 1141, 10.1023/A:1025032511040
Lennernäs H., 1996, Int. J. Pharm., 127, 103, 10.1016/0378-5173(95)04204-0
Lee K.-J., 2005, Eur. J. Pharm. Sci., 25, 193, 10.1016/j.ejps.2005.02.012
Custodio J. M., 2008, Adv. Drug Delivery Rev., 60, 717, 10.1016/j.addr.2007.08.043
Cao X., 2005, Mol. Pharmaceutics, 2, 329, 10.1021/mp0499104
Dahan A., 2009, Drug Metab. Dispos., 37, 2028, 10.1124/dmd.109.028282
Valenzuela B., 2004, J. Pharm. Sci., 93, 1641, 10.1002/jps.20071
